Stay updated on Intratumoral SD-101 + Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.

Latest updates to the Intratumoral SD-101 + Pembrolizumab Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedAdded a label 'Revision: v3.4.2' to the page. The previous 'Revision: v3.4.1' label is no longer displayed.SummaryDifference0.0%

- Check17 days agoChange DetectedRevision: v3.4.1 was added in the page footer, replacing v3.4.0. This is a minor UI update and does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedA glossary toggle was added; QA-related labels and capitalization were updated (e.g., 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'), and the footer now shows 'Revision: v3.4.0'.SummaryDifference0.1%

- Check39 days agoChange DetectedThe page metadata shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded Location sections for Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa, Michigan, Minnesota, Nebraska, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Utah, Virginia, West Virginia, New South Wales, South Australia, and Western Australia. The page revision was updated to v3.3.3.SummaryDifference2%

- Check89 days agoChange DetectedFooter now shows Revision: v3.3.2 (replacing v3.3.1). No visible changes to study content or page behavior.SummaryDifference0.0%

Stay in the know with updates to Intratumoral SD-101 + Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral SD-101 + Pembrolizumab Clinical Trial page.